Measles, Mumps, and Rubella Vaccines (Combined)
- Atc Codes:J07BD52
Table of contents
- Brand Names
- Drug Combinations
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Dosage
Brand Names
Europe
Austria: MMRVaxpro, Priorix; Belgium: M.M.R. Vaxpro, Priorix; Bulgaria: MMRVaxpro, Priorix, Trimovax Merieux; Cyprus: MMRVaxpro, Priorix; Czech Republic: MMR II, MMRVaxpro, Priorix, Trivivac; Denmark: Priorix; Estonia: MMRVaxpro, Priorix; Finland: Priorix; France: MMR Triplovax, MMRVax, MMRVaxpro, Priorix; Germany: MMRVaxpro, Priorix; Greece: MMR-II, MMRVaxpro, Priorix; Hungary: MMRVaxpro, Priorix; Ireland: MMRVaxpro, Priorix; Italy: MMRVaxpro, Priorix; Latvia: MMRVaxpro, Priorix; Lithuania: MMRVaxpro, Priorix; Malta: MMRVaxpro, Priorix; Netherlands: MMRVaxpro, Priorix; Poland: MMRVaxpro, Priorix; Portugal: MMRVaxpro, Priorix; Romania: MMRVaxpro, Priorix; Slovakia: MMRVaxpro, Priorix; Slovenia: MMRVaxpro, Priorix; Spain: Priorix; Sweden: MMRVaxpro, Priorix; UK: MMRvaxpro, Priorix.
North America
Canada: MMR II, Priorix; USA: MMR II.
Latin America
Mexico: Morupar, Priorix.
Drug combinations
Measles, Mumps, Rubella and Varicella Virus Vaccine
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Vaccines. (ATC-Code: J07BD52).
Mechanism of action
As a live, attenuated vaccine, it offers active immunity to disease caused by measles, mumps, and rubella viruses.
Therapeutic use
Active immunity to measles, mumps, and rubella viruses in individuals ≥12 months of age.
Pregnancy and lactiation implications
Pregnancy should be avoided for 3 months following vaccination.
Unlabeled use
Contraindications
Hypersensitivity to measles, mumps, and rubella vaccine or any component of the formulation. Hypersensitivity to neomycin or gelatin. Current febrile respiratory illness or other febrile infection. Patients receiving immunosuppressive therapy. Primary and acquired immunodeficiency states. Blood dyscrasias, cancers affecting bone marrow or lymphatic systems. Children with active untreated tuberculosis. Pregnancy.
Warnings and precautions
Use in existing thrombocytopenia may result in more severe reduction in platelets (avoid use in previous history of postvaccination thrombocytopenia). Severe allergic reactions including anaphylaxis reported rarely. Use with extreme caution in immediate-type hypersensitivity reactions to eggs. Vaccine should not be administered to severely immunocompromised persons with exception of asymptomatic children with HIV. Severely immunocompromised patients and symptomatic HIV-infected patients exposed to measles should receive immune globulin, regardless of prior vaccination status. Patients with minor illnesses (diarrhea, mild upper respiratory tract infection with or without low grade fever or other illnesses with low-grade fever) may receive vaccine. Leukemia patients in remission and who have not received chemotherapy for at least 3 months may be vaccinated. Use with caution in history of cerebral injury, convulsions, or other conditions where stress due to fever should be avoided.